Background: The World Health Organization recommends intradermal (ID) administration of rabies vaccine for preexposure prophylaxis.
Methods: In a randomized trial in adults assigned to 1 of 6 treatment groups (ID vs intramuscular [IM], 2 vs 3 doses, and controls), rabies neutralizing antibody titers were measured to 1 year postvaccination.
Results: ID vaccination produced acceptable antibody levels in all subjects (2- and 3-dose groups). At day 365, acceptable levels were 40% for IM and 50% for ID 2-dose schedule, and 70% for IM and 60% for ID 3-dose schedule.
Conclusions: ID rabies vaccination induces acceptable antibody titers at a fraction of the dose.
Clinical Trials Registration: NCT02374814.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/infdis/jiz645 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rabies virus causes nearly 60,000 human deaths annually. Antibodies that target the rabies glycoprotein (G) are being developed as post-exposure prophylactics, but mutations in G can render such antibodies ineffective. Here, we use pseudovirus deep mutational scanning to measure how all single amino-acid mutations to G affect cell entry and neutralization by a panel of antibodies.
View Article and Find Full Text PDFBurden of human rabies disease: its potential prevention by means of Rabipur vaccine.
J Prev Med Hyg
September 2024
Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
Rabies is a zoonotic viral disease transmitted mainly by bites of infected animals, especially dogs, which are responsible for 99% of human cases. Despite being preventable, it remains a neglected disease in low-income countries, with approximately 60,000 deaths per year, mostly concentrated in Africa and Asia. The real worldwide burden of rabies is probably underestimated, as death-reporting systems are inadequate and active surveillance is limited.
View Article and Find Full Text PDFA nucleoside-modified rabies mRNA vaccine induces long-lasting and comprehensive immune responses in mice and non-human primates.
Mol Ther
December 2024
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211112, China; Institute of Translational Medicine, China Pharmaceutical University, Nanjing 211112, China. Electronic address:
Rabies is a lethal zoonotic infectious disease. Vaccines against the rabies virus have significantly reduced the number of deaths from the disease. However, all the licensed rabies vaccines are inactivated vaccines, which have limited immunogenicity and complicated immunization procedures.
View Article and Find Full Text PDFCombining genomics and epidemiology to investigate a zoonotic outbreak of rabies in Romblon Province, Philippines.
Nat Commun
December 2024
Boyd Orr Centre for Population and Ecosystem Health, School of Biodiversity, One Health & Veterinary Medicine, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
Rabies is a viral zoonosis that kills thousands of people annually in low- and middle-income countries across Africa and Asia where domestic dogs are the reservoir. 'Zero by 30', the global strategy to end dog-mediated human rabies, promotes a One Health approach underpinned by mass dog vaccination, post-exposure vaccination of bite victims, robust surveillance and community engagement. Using Integrated Bite Case Management (IBCM) and whole genome sequencing (WGS), we enhanced rabies surveillance to detect an outbreak in a formerly rabies-free island province in the Philippines.
View Article and Find Full Text PDFClinical advancements in mRNA vaccines against viral infections.
Clin Immunol
December 2024
Department of Microbiology, Gachon University College of Medicine, Incheon, Republic of Korea; Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea; Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, Republic of Korea; Korea mRNA Vaccine Initiative, Gachon University, Seongnam, Republic of Korea. Electronic address:
Over the last decade, mRNA vaccines development has shown significant advancement, particularly during the COVID-19 pandemic. This comprehensive review examines the efficacy of pivotal vaccines against emerging COVID-19 variants and strategies for enhancing vaccine effectiveness. It also explores the versatility of mRNA technology in addressing other infectious diseases such as influenza, respiratory syncytial virus, HIV, cytomegalovirus, Ebola, Zika, Rabies, and Nipah viruses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!